There are two Phase III products - they haven't discussed pricing/market potential for either yet, but the lens replacement market is 3M+ procedures per year and growing (as the baby boomers age), so even at $100 per procedure, it is $300M+ for that drug alone, so with the company valued at less than $250M right now, it is an easy double over the next year.
Tred do you know what other alternatives are available for lens replacement other than OMER's drug in PIII. I am trying to figure out what the market penetration will be. This looks like a good pick but I am still not in it.
What is your next pick for a SRPT-like winning? I don't see any now.